# COLchicine On-admission to Reduce Inflammation in Acute Coronary Syndrome (COLOR-ACS)

> **NCT05250596** · PHASE2 · COMPLETED · sponsor: **Azienda USL Toscana Centro** · enrollment: 182 (actual)

## Conditions studied

- Non ST Segment Elevation Acute Coronary Syndrome

## Interventions

- **DRUG:** Colchicine
- **DRUG:** Atorvastatin

## Key facts

- **NCT ID:** NCT05250596
- **Lead sponsor:** Azienda USL Toscana Centro
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-02-24
- **Primary completion:** 2024-02-24
- **Final completion:** 2024-05-30
- **Target enrollment:** 182 (ACTUAL)
- **Last updated:** 2024-07-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05250596

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05250596, "COLchicine On-admission to Reduce Inflammation in Acute Coronary Syndrome (COLOR-ACS)". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT05250596. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*